Quark Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: Fremont CA United States (1994)
Status: Defunct (2022)

Organization Overview

First Clinical Trial
2007
NCT00725686
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Quark Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (2)

qpi-1002 (3 trials)

qpi-1007 (3 trials)

Drugs in Phase 2 Trials (4)

i5np (3 trials)

pf-04523655 (4 trials)

ranibizumab (lucentis) (2 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Atrophy (Phase 1)

Choroidal Neovascularization (Phase 2)

Delayed Graft Function (Phase 3)

Diabetes Complications (Phase 2)

Diabetic Retinopathy (Phase 2)

Edema (Phase 2)

Glaucoma (Phase 2)

Glaucoma, Angle-Closure (Phase 2)

Ischemia (Phase 3)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Neovascularization, Pathologic (Phase 2)

Optic Atrophy (Phase 1)

Optic Nerve Diseases (Phase 3)

Optic Neuropathy, Ischemic (Phase 3)

Renal Insufficiency (Phase 1)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 6